Puma Biotechnology Q1 2024 Adj EPS $(0.05) Beats $(0.22) Estimate, Sales $43.800M Beat $41.050M Estimate
Puma Biotechnology Q1 2024 Adj EPS $(0.05) Beats $(0.22) Estimate, Sales $43.800M Beat $41.050M Estimate
Puma Biotechnology 2024年第一季度調整後每股收益美元（0.05）超過預期（0.22）美元，銷售額438億美元超過410.5億美元的預期
Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.22) by 77.27 percent. This is a 155.56 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $43.800 million which beat the analyst consensus estimate of $41.050 million by 6.70 percent. This is a 17.05 percent decrease over sales of $52.800 million the same period last year.
彪馬生物技術（納斯達克股票代碼：PBYI）公佈的季度虧損爲每股0.05美元，比分析師普遍預期的0.22美元（0.22美元）高出77.27％。與去年同期的每股收益0.09美元相比，下降了155.56％。該公司公佈的季度銷售額爲438億美元，比分析師普遍預期的410.5億美元高出6.70％。這比去年同期的528億美元銷售額下降了17.05％。